Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CCR9 | P51686 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499583 | 0.86 | ALDH1A1 (0.47) | MAPTSMN1; SMN2ALDH1A1GAAHPGD | |
| SCHEMBL6442541 | 0.85 | ALDH1A1 (0.46) | MAPTSMN1; SMN2ALDH1A1GAAHPGD | |
| SCHEMBL9063310 | 0.84 | GAA (0.59) | MAPTHTTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL499767 | 0.83 | MAPT (0.67) | MAPTHTTALDH1A1RAB9AGAA | |
| SCHEMBL13979890 | 0.82 | GAA (0.47) | MAPTHTTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL12290954 | 0.82 | MAPT (0.52) | MAPTHTTSMN1; SMN2ALDH1A1CCR9 | |
| SCHEMBL4844927 | 0.82 | MAPT (0.70) | MAPTHTTSMN1; SMN2ALDH1A1CCR9 | |
| SCHEMBL29809563 | 0.81 | KDM4E (0.65) | MAPTHTTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17019 | 0.81 | KDM4E (0.65) | MAPTHTTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL499641 | 0.81 | ALDH1A1 (0.43) | MAPTHTTSMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2230907-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2147008-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | Bristol-Myers Squibb Company (US) | 2010-01-27 | — | — | EP | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1791852-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1791852-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008144346-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR THEIR PREPARATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144346-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR THEIR PREPARATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| EP-1791852-A2 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | Brystol-Myers Squibb Company (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006034489-A2 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063722-A1 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, SLC2A1 | MAPT 862/4885HTT 887/4885SMN1; SMN2 3001/4885 |
| US-20060063722-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, GCG | MAPT 1260/4885HTT 1943/4885SMN1; SMN2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.